ArticleTransplantation2013
LVAD implant as a bridge to heart transplantation is associated with allosensitization as measured by single antigen bead assay.
Article in Transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 45 citations in OpenAlex.
- Interplay of Pulmonary Hypertension and the Effects of Panel-Reactive Antibodies on Outcomes of Heart Transplant Recipients Bridged With Left Ventricular Assist Device.Journal of the American Heart Association · 2026Article
- Early outcomes in heart transplantation using donation after circulatory death donors in patients bridged with durable left ventricular assist devices.The Journal of thoracic and cardiovascular surgery · 2025Article
- Outcomes after heart transplantation in patients who have undergone a bridge-to-bridge strategy.JTCVS open · 2022Article
- Impact of pretransplant left ventricular assist device support duration on outcome after heart transplantation.Interactive cardiovascular and thoracic surgery · 2022Article
- Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.Frontiers in immunology · 2021Review
- Current Desensitization Strategies in Heart Transplantation.Frontiers in immunology · 2021Review
- The Approach to Antibodies After Heart Transplantation.Current transplantation reports · 2017Article
- Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2017Article
- Influence of durable mechanical circulatory support and allosensitization on mortality after heart transplantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2016Article
- Characterization of ventricular assist device-mediated sensitization in the bridge-to-heart-transplantation patient.The Journal of thoracic and cardiovascular surgery · 2015Article
- Human leukocyte antigens and alloimmunization in heart transplantation: an open debate.Journal of cardiovascular translational research · 2014Review
- Donor selection in heart transplantation.Journal of thoracic disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLeft ventricular assist devices (LVAD) as a bridge (BTT) to heart transplantation (HTX) may be limited by the formation of anti-human leukocyte antigen antibodies. Whether sensitization occurs with continuous axial flow LVAD implant as assessed by single antigen bead (SAB) assay is unknown.
methodsCytotoxic panel-reactive antibody (PRA) and SAB assays were analyzed in HTX recipients undergoing LVAD implant as a BTT. Sensitization was defined as peak anti-human leukocyte antigen antibody values of more than 2000 mean fluorescence intensity because these values have been found to correlate with flow cytometric crossmatch results.
resultsLVADs were implanted as BTT in 30 patients. There were 7% (2 of 30) of patients before LVAD implant and no patients after LVAD implant with PRA more than 10%. However, 20% (6 of 30) of patients before LVAD and 53% (16 of 30) after LVAD were sensitized as measured by SAB (P=0.024). At HTX, 47% (14 of 30) of patients remained sensitized. A positive virtual crossmatch was observed in 28% (4 of 14) of the sensitized patients at HTX. There was no difference between the sensitized and nonsensitized groups (P>0.4 for all) in usage of blood products (6411 vs. 6339 units) and time to HTX (28,663 vs. 25,748 days), and 1 year after HTX, there were no differences in rejection (total rejection score 0.30 vs. 0.37) and survival (93% vs. 88%).
conclusionAllosensitization after LVAD is common despite cytotoxic PRA being negative. One year after HTX, this sensitization does not translate into increased acute cellular or antibody-mediated rejection or reduced survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.